Piper Sandler Lowers Medtronic (NYSE:MDT) Price Target to $85.00

Medtronic (NYSE:MDT) had its price target lowered by equities researchers at Piper Sandler from $91.00 to $85.00 in a report issued on Thursday,MarketScreener reports. The firm currently has a “neutral” rating on the medical technology company’s stock. Piper Sandler’s price objective would indicate a potential upside of 3.32% from the stock’s previous close.

Several other equities analysts also recently weighed in on the stock. Stifel Nicolaus set a $80.00 price target on shares of Medtronic in a research note on Wednesday. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a report on Thursday. The Goldman Sachs Group decreased their target price on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday. Mizuho lowered their target price on Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, BTIG Research set a $90.00 price target on Medtronic in a research report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $98.45.

Medtronic Price Performance

Shares of MDT traded up $4.32 during trading hours on Thursday, hitting $82.27. 2,865,182 shares of the stock were exchanged, compared to its average volume of 9,074,854. The stock’s 50-day moving average price is $81.67 and its two-hundred day moving average price is $92.21. Medtronic has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company has a market cap of $105.63 billion, a price-to-earnings ratio of 22.92, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same quarter last year, the firm posted $1.62 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts expect that Medtronic will post 5.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MDT. Artisan Partners Limited Partnership increased its holdings in Medtronic by 2.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after purchasing an additional 31,314 shares during the last quarter. CSM Advisors LLC lifted its stake in Medtronic by 13.2% during the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after purchasing an additional 33,167 shares in the last quarter. SageView Advisory Group LLC boosted its position in shares of Medtronic by 164.8% during the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the period. Madison Asset Management LLC boosted its position in shares of Medtronic by 15.0% during the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after buying an additional 25,527 shares during the period. Finally, Bleakley Financial Group LLC grew its stake in shares of Medtronic by 17.8% in the third quarter. Bleakley Financial Group LLC now owns 87,313 shares of the medical technology company’s stock valued at $8,316,000 after buying an additional 13,177 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of estimates, which reinforced the recent stock move higher.
• Positive Sentiment: Cardiac Ablation Solutions revenue surged 78% globally, helping offset margin pressure and signaling strong demand in a key growth franchise.
• Positive Sentiment: Management lifted its quarterly dividend to $0.72 per share and kept FY2027 growth targets intact, supporting the case for continued operational momentum.
• Positive Sentiment: Medtronic also announced new strategic investments and FDA-related submissions to expand its Hugo robotic-assisted surgery platform, which could add future growth opportunities. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
• Neutral Sentiment: Several analysts lowered price targets this morning, but most kept constructive ratings such as overweight, outperform, or buy, suggesting valuation concerns rather than a changed bullish thesis.
• Neutral Sentiment: Wells Fargo cut its target to $102 from $114 and Leerink cut to $104 from $117, while Robert W. Baird reduced its target to $85 and kept a neutral rating.
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate, which may temper some of the post-earnings enthusiasm.
• Negative Sentiment: Margins remain a focus as the company flagged tariff and cost headwinds, which could pressure profitability even as sales improve.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).